Prostate cancer types of cells, [Immunotherapy in the treatment of genitourinary cancers]


Nivolumab treatment became the new standard of care in locally advanced or metastatic renal cell cancer after failure on tyrosine kinase inhibitor treatment. Sipuleucel-T prolonged survival in patients with asymptomatic or minimally symptomatic metastatic castration resistant prostate cancer but had no effect on progression-free survival.

The hormone-sensitive cells die and the hormone-resistant cells overgrow, resulting in disease progression. The drug of choice for secondary treatment is estramustine Estracyt.

Mumina prostatitis visszajelzés Krónikus prosztatitis kezelési rendszerei exacerbációban

The success of the therapy is followed by changes of the prostate-specific antigen level and Karnofsky scale. In the present study, the results of estramustine treatment of 79 patients with advanced prostate cancer in 12 hospitals were evaluated.

a prosztatitisből származó haj kiürülhet A prosztatitis hatékonyság kezelése

The mean prostate-specific antigen level improved for 6 months, but rose from the ninth month on. The improvement in the subjective condition of the patients paralleled the change in the prostate-specific antigen level.

MeSH terms

The short time of improvement was a consequence of the very high prostate-specific antigen level and the poor general condition. Estramustine administration is recommended when the prostate-specific antigen level becomes more than doubled following primary treatment.

Prostatitis és betegség Prostatitis a férfiaknál a pieches- szel

If the prostate-specific antigen level has not decreased after treatment for 3 months, the secondary strategy is to apply chemotherapy. Publication types.